Carol Kelly to helm new NACDS department

ALEXANDRIA, Va. The National Association of Chain Drug Stores announced today that as of January, Carol Kelly will be coming on board in the newly created position of senior vice president of government affairs and public policy.

Kelly currently serves as senior executive advisor of external affairs to the secretary of Health and Human Services, Michael Leavitt. In this role she served as the main HHS liaison to the White House Office of Public Liaison and to the Partnership for Value-driven Health Care, an employer health care reform coalition.

“One look at Carol’s background and it is readily apparent that she is ideal for this role at NACDS. Carol is considered as one of the great policy experts in the area of health care,” said Steve Anderson, NACDS president and chief executive officer. “She has had an extremely distinguished career in senior government positions, in corporate leadership roles, and as a senior executive in a health care trade association.”

Prior to her current position, Kelly served for two years as the director of the Office of Policy for HHS’ Centers for Medicare and Medicaid Services, and before that was executive vice president for federal legislative policy and healthcare system reform at the Advanced Medical Technology Association.

Kelly has also served as a vice president, with responsibility for government affairs, for Premier, UnitedHealth Care and MetraHealth, as well as healthcare advocacy for MetLife and Equitable Life. “Carol understands the issues, the players and the landscape of health care. She has considerable experience in both regulation and legislation, and the interaction between the two,” Anderson said.

Kelly’s new department, according to Anderson, “will greatly enhance the effectiveness and profile of the federal and state legislative and regulatory activities of NACDS.” The restructuring will combine the current government affairs department and the current policy and pharmacy regulatory affairs department.

“We are building a culture at NACDS that is focused on achieving results. We are doing this through collective staff accountability and true integration of policy, state and federal government affairs, grassroots, communications, coalition-building and expertise in pharmacy practice and front-end issues. The staff’s embracing of these principles, as well as its talent and tenacity, shine through in recent successes, and in our commitment to ongoing issues. Carol Kelly will bring to this important work a second-to-none professional portfolio, and we are enthusiastic about her taking the helm of a newly aligned department that is poised to deliver results for chain community pharmacy and the patients it serves,” Anderson said.

This is in response to an agreement the companies signed with Purdue Pharma, who manufactures the brand version, Oxycontin, which is used for the management of moderate to severe pain when a continuous around-the-clock analgesic is needed for an extended period of time. The agreement said that IMPAX acknowledged that Purdue’s patents for Oxycontin were valid, enforceable and infringed on by their generic version. Purdue in return, allowed the companies to continue selling the product on the market until June 14, and to resume the distribution at a future date for a limited period of time.

The sales of the generic are expected to continue until around Jan. 28, 2008, or until the company’s sales quota under the license agreement with Purdue has been reached.

Isis grants Excaliard license for development of antisense drugs

CARLSBAD and ENCINITAS, Calif. Isis and Excaliard Pharmaceuticals have entered into an agreement to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring. Isis has granted Excaliard an exclusive worldwide license for the development and commercialization of certain antisense drugs.

Under the agreement, Excaliard made an upfront payment in the form of equity and paid $1 million cash to Isis for the licensing of a particular gene target. Isis will also be eligible to receive development milestones and royalties on antisense drugs developed by Excaliard.

“Isis has made superb progress in the development of second-generation antisense drugs over the last few years, as evidenced by its clinical pipeline and current collaborations with companies such as Bristol-Myers Squibb, Eli Lilly and Ortho-McNeil, among others,” said Excaliard co-founder J. Gordon Foulkes, acting chief executive officer for Excaliard and managing director of RiverVest Venture Partners. “Having access to Isis’ antisense technology and expertise provides a great opportunity for Excaliard.”

RELATED NEWS

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare Company, has reached a big number with its remote psychiatry offering. The Tukwila, Wash.-based company announced Tuesday that it had facilitated more than 100,000 telepsych consultations on its video conferencing platform.
Genoa attributes the milestone to its recent buildup of its telepsychiatry operations, which grew to include 35 in 2017 from 20 at the start of the year, and included 250 providers. In 2017, the company grew to serve more than 2,500 patients per week.

This year's flu continues to be Texas big, according to the Walgreens Flu Index released Wednesday, as the top 10 communities experiencing the greatest amount of flu incidence were all located in the Lone Star State for the week ended Jan. 6.
Iowa, Idaho and Arkansas rank behind Texas in terms of flu activity. And Montana, Idaho and Iowa ranked highest among states experiencing flu activity gains.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry